Prevalence and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC).
Prevalence and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC).
复制标题
DOI：
--
复制
发表时间：
2003
期刊：
影响因子：
3
通讯作者：
O. Turken;E. Kunter;H. Çermik;T. Ișitmangil;G. Kandemir;M. Yaylacı;A. Ozturk
中科院分区：
文献类型：
--
作者：
O. Turken;E. Kunter;H. Çermik;T. Ișitmangil;G. Kandemir;M. Yaylacı;A. Ozturk
c-erbB2癌蛋白在大约三分之一的非小细胞肺癌（NSCLC）患者中高度表达。我们确定了c-erbB2在非小细胞肺癌患者中的表达状态，并研究了其与疾病分期、组织学类型和治疗反应的相关性。采用免疫组化多克隆抗体检测84例患者c-erbB2的表达。采用临床试验分析（CTA）评分标准评价染色（0 ~ +3）。35%的病例检测到c-erbB2过表达。更高阶段（iib - iv期）的肿瘤在腺癌（ADC）中更常呈c-erbB2阳性（p=0.04）。此外，ADC患者的c-erbB2评分与疾病分期有相关性（p=0.03）。我们的研究没有证明c-erbB2过表达与化疗反应有关。我们得出结论，c-erbB2过表达可能是评估非小细胞肺癌患者肿瘤进展的预后标志物，但必须在更大的患者群体中进行进一步的研究。
The c-erbB2 oncoprotein is highly expressed in approximately one third of non-small cell lung cancer (NSCLC) patients. We determined the status of c-erbB2 expression in our patients with NSCLC and investigated its correlation with disease stage, histological type and response to treatment. Eighty-four patients were examined for the expression of c-erbB2 by immunohistochemistry using a polyclonal antibody. The scoring criteria of Clinical Trial Assay (CTA) were used to evaluate staining (0 to +3). c-erbB2 overexpression was determined in 35% of the cases. Tumors from higher stage disease (stage IIIb-IV) were more often c-erbB2 positive in adenocarcinoma (ADC) (p=0.04). In addition, there was an association between c-erbB2 score and disease stage in ADC patients (p=0.03). Our study did not demonstrate an association of c-erbB2 overexpression with response to chemotherapy. We conclude that c-erbB2 overexpression may be a prognostic marker for evaluating tumor progression in NSCLC patients but further studies must be performed with larger patient populations.